A Multi-Center Phase 1, Dose-Escalation Trial to Determine the Safety and Pharmacokinetics/Pharmacodynamics of RDEA119, A MEK Inhibitor, in Advanced Cancer Patients.

Trial Profile

A Multi-Center Phase 1, Dose-Escalation Trial to Determine the Safety and Pharmacokinetics/Pharmacodynamics of RDEA119, A MEK Inhibitor, in Advanced Cancer Patients.

Completed
Phase of Trial: Phase I

Latest Information Update: 06 Jan 2015

At a glance

  • Drugs Refametinib (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors Bayer
  • Most Recent Events

    • 08 Jul 2011 Planned end date changed from Jun 2011 to Dec 2011 as reported by ClinicalTrials.gov.
    • 19 May 2011 Status changed from active, no longer recruiting to completed.
    • 18 May 2011 Results will be presented at ASCO 2011, according to a Bayer Healthcare media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top